A roll of the dice

Regulation

There may be better days to come for the cancer immunotherapy space, but last Wednesday was not one of them. The Oncologic Drugs Advisory Committee's thumbs-down for IDM Pharma Inc.'s Junovan mifamurtide for osteosarcoma and the approvable letter for Dendreon Corp.'s Provenge sipuleucel-T prostate cancer vaccine underlined that FDA is in no mood to relax its demand for well-designed trials that meet their primary endpoint...